| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 40 | 2016 | 178 | 4.980 |
Why?
|
| Skin | 24 | 2016 | 187 | 2.040 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2024 | 66 | 1.600 |
Why?
|
| Facial Dermatoses | 9 | 2016 | 10 | 1.560 |
Why?
|
| Skin Diseases | 14 | 2013 | 30 | 1.220 |
Why?
|
| Lasers, Solid-State | 7 | 2016 | 12 | 1.210 |
Why?
|
| Humans | 170 | 2024 | 43102 | 1.150 |
Why?
|
| Paraneoplastic Syndromes | 3 | 2013 | 4 | 1.030 |
Why?
|
| Hyperpigmentation | 5 | 2015 | 10 | 1.020 |
Why?
|
| Regenerative Medicine | 2 | 2022 | 10 | 0.970 |
Why?
|
| Female | 113 | 2024 | 24698 | 0.920 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 21 | 0.900 |
Why?
|
| Granuloma | 5 | 2013 | 24 | 0.900 |
Why?
|
| Melanoma | 3 | 2015 | 110 | 0.880 |
Why?
|
| Male | 89 | 2024 | 23409 | 0.880 |
Why?
|
| Hair Follicle | 3 | 2014 | 12 | 0.850 |
Why?
|
| Head and Neck Neoplasms | 3 | 2016 | 81 | 0.850 |
Why?
|
| Hair Diseases | 3 | 2013 | 5 | 0.840 |
Why?
|
| Adult | 78 | 2024 | 13872 | 0.840 |
Why?
|
| Electromyography | 1 | 2024 | 69 | 0.840 |
Why?
|
| Tacrolimus | 3 | 2013 | 16 | 0.810 |
Why?
|
| Electroencephalography | 1 | 2024 | 139 | 0.790 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 9 | 0.770 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 10 | 0.770 |
Why?
|
| Nevus | 2 | 2012 | 5 | 0.770 |
Why?
|
| Foot Dermatoses | 2 | 2014 | 2 | 0.760 |
Why?
|
| Dermatitis, Exfoliative | 2 | 2013 | 2 | 0.740 |
Why?
|
| Diagnosis, Differential | 34 | 2016 | 238 | 0.730 |
Why?
|
| Glomus Tumor | 2 | 2012 | 2 | 0.730 |
Why?
|
| Edema | 3 | 2016 | 26 | 0.720 |
Why?
|
| Dermatologic Agents | 5 | 2015 | 9 | 0.690 |
Why?
|
| Low Back Pain | 1 | 2022 | 101 | 0.690 |
Why?
|
| Adipose Tissue | 2 | 2012 | 182 | 0.690 |
Why?
|
| Middle Aged | 64 | 2016 | 12222 | 0.680 |
Why?
|
| Young Adult | 23 | 2016 | 5080 | 0.680 |
Why?
|
| Acrodermatitis | 3 | 2009 | 4 | 0.660 |
Why?
|
| Erythema | 5 | 2016 | 10 | 0.660 |
Why?
|
| Scalp | 7 | 2013 | 12 | 0.600 |
Why?
|
| Skin Diseases, Vesiculobullous | 6 | 2009 | 7 | 0.580 |
Why?
|
| Trichophyton | 4 | 2011 | 5 | 0.560 |
Why?
|
| Treatment Outcome | 23 | 2016 | 1604 | 0.560 |
Why?
|
| Laser Therapy | 5 | 2011 | 25 | 0.520 |
Why?
|
| Porokeratosis | 4 | 2010 | 4 | 0.520 |
Why?
|
| Hamartoma | 3 | 2012 | 6 | 0.520 |
Why?
|
| Skin Ulcer | 2 | 2015 | 6 | 0.520 |
Why?
|
| Tinea | 3 | 2011 | 8 | 0.510 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2014 | 5 | 0.510 |
Why?
|
| Skin Aging | 5 | 2014 | 10 | 0.510 |
Why?
|
| Granuloma, Foreign-Body | 3 | 2012 | 4 | 0.510 |
Why?
|
| Nevus, Pigmented | 3 | 2013 | 6 | 0.500 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 6 | 2016 | 6 | 0.490 |
Why?
|
| Biopsy | 9 | 2016 | 177 | 0.490 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2016 | 1 | 0.490 |
Why?
|
| Hyaluronic Acid | 2 | 2014 | 36 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2013 | 220 | 0.480 |
Why?
|
| Immunosuppressive Agents | 3 | 2011 | 94 | 0.480 |
Why?
|
| Lichen Planus | 3 | 2011 | 5 | 0.460 |
Why?
|
| Xanthogranuloma, Juvenile | 1 | 2015 | 1 | 0.460 |
Why?
|
| Acne Vulgaris | 3 | 2011 | 7 | 0.460 |
Why?
|
| Callosities | 1 | 2014 | 1 | 0.450 |
Why?
|
| Myxoma | 2 | 2012 | 5 | 0.450 |
Why?
|
| Immunocompromised Host | 3 | 2011 | 26 | 0.450 |
Why?
|
| Bleomycin | 1 | 2014 | 20 | 0.440 |
Why?
|
| Biopsy, Needle | 20 | 2016 | 59 | 0.440 |
Why?
|
| Child | 25 | 2016 | 3443 | 0.440 |
Why?
|
| Immunohistochemistry | 26 | 2016 | 934 | 0.440 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 2014 | 2 | 0.440 |
Why?
|
| Thymus Neoplasms | 1 | 2014 | 4 | 0.440 |
Why?
|
| Antifungal Agents | 4 | 2011 | 169 | 0.440 |
Why?
|
| Acanthoma | 1 | 2014 | 1 | 0.430 |
Why?
|
| Keratosis, Seborrheic | 1 | 2014 | 2 | 0.430 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 51 | 0.430 |
Why?
|
| Dermatitis | 2 | 2015 | 10 | 0.430 |
Why?
|
| Drug Resistance, Fungal | 2 | 2011 | 33 | 0.430 |
Why?
|
| Aged | 35 | 2016 | 8214 | 0.420 |
Why?
|
| Dermatitis, Atopic | 1 | 2013 | 10 | 0.420 |
Why?
|
| Movement | 3 | 2024 | 119 | 0.420 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2010 | 4 | 0.410 |
Why?
|
| Lichen Nitidus | 1 | 2013 | 1 | 0.400 |
Why?
|
| Penile Diseases | 1 | 2013 | 6 | 0.400 |
Why?
|
| Alopecia | 1 | 2013 | 11 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 306 | 0.390 |
Why?
|
| Angiomyolipoma | 1 | 2012 | 2 | 0.390 |
Why?
|
| Foot Diseases | 1 | 2012 | 2 | 0.390 |
Why?
|
| Skull | 1 | 2013 | 28 | 0.390 |
Why?
|
| Lipomatosis | 1 | 2012 | 1 | 0.390 |
Why?
|
| Child, Preschool | 13 | 2015 | 1546 | 0.390 |
Why?
|
| Dextrans | 1 | 2012 | 29 | 0.380 |
Why?
|
| Vascular Neoplasms | 2 | 2010 | 2 | 0.380 |
Why?
|
| Prurigo | 1 | 2012 | 2 | 0.380 |
Why?
|
| Pigmentation Disorders | 1 | 2012 | 3 | 0.380 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 316 | 0.370 |
Why?
|
| Antineoplastic Agents | 5 | 2016 | 1019 | 0.370 |
Why?
|
| Dura Mater | 1 | 2012 | 1 | 0.370 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 5 | 0.370 |
Why?
|
| Molluscum Contagiosum | 1 | 2011 | 2 | 0.360 |
Why?
|
| Fasciitis | 2 | 2009 | 3 | 0.360 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.360 |
Why?
|
| Retrospective Studies | 19 | 2016 | 2544 | 0.350 |
Why?
|
| Dermatofibrosarcoma | 1 | 2011 | 1 | 0.350 |
Why?
|
| Fanconi Anemia | 1 | 2011 | 8 | 0.350 |
Why?
|
| Lasers, Gas | 1 | 2011 | 3 | 0.350 |
Why?
|
| Punctures | 1 | 2011 | 6 | 0.350 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2012 | 20 | 0.350 |
Why?
|
| Photochemotherapy | 2 | 2011 | 43 | 0.340 |
Why?
|
| Aminolevulinic Acid | 1 | 2011 | 7 | 0.340 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2016 | 154 | 0.340 |
Why?
|
| Adolescent | 24 | 2016 | 6081 | 0.340 |
Why?
|
| Fingers | 1 | 2011 | 21 | 0.340 |
Why?
|
| Mycobacterium Infections | 1 | 2010 | 16 | 0.330 |
Why?
|
| Hemangioma | 2 | 2007 | 7 | 0.330 |
Why?
|
| Mycobacterium | 1 | 2010 | 16 | 0.330 |
Why?
|
| Triazoles | 1 | 2011 | 102 | 0.330 |
Why?
|
| Lymphadenitis | 1 | 2010 | 3 | 0.330 |
Why?
|
| Uterine Neoplasms | 2 | 2009 | 53 | 0.320 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2010 | 13 | 0.320 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2010 | 13 | 0.320 |
Why?
|
| Pyrimidines | 1 | 2011 | 139 | 0.320 |
Why?
|
| Lymphatic Abnormalities | 1 | 2010 | 1 | 0.320 |
Why?
|
| Port-Wine Stain | 1 | 2010 | 2 | 0.320 |
Why?
|
| Noonan Syndrome | 1 | 2010 | 3 | 0.320 |
Why?
|
| Amyloidosis | 2 | 2008 | 37 | 0.320 |
Why?
|
| Republic of Korea | 6 | 2015 | 141 | 0.300 |
Why?
|
| Epithelial Cells | 1 | 2012 | 434 | 0.300 |
Why?
|
| Paraproteinemias | 2 | 2008 | 4 | 0.300 |
Why?
|
| Carcinoma, Papillary | 1 | 2009 | 15 | 0.290 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2008 | 1 | 0.290 |
Why?
|
| Neurofibromatosis 2 | 1 | 2008 | 2 | 0.290 |
Why?
|
| Esophageal Neoplasms | 1 | 2010 | 140 | 0.290 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2009 | 44 | 0.290 |
Why?
|
| Purpura | 1 | 2008 | 3 | 0.290 |
Why?
|
| Eyelid Diseases | 1 | 2008 | 5 | 0.290 |
Why?
|
| Drug Eruptions | 4 | 2015 | 8 | 0.280 |
Why?
|
| Severity of Illness Index | 14 | 2016 | 719 | 0.280 |
Why?
|
| Knee | 3 | 2009 | 7 | 0.280 |
Why?
|
| Eccrine Glands | 5 | 2010 | 6 | 0.270 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 48 | 0.270 |
Why?
|
| POEMS Syndrome | 1 | 2007 | 1 | 0.270 |
Why?
|
| Follow-Up Studies | 13 | 2015 | 1067 | 0.270 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 2 | 2003 | 4 | 0.250 |
Why?
|
| Dermatomycoses | 3 | 2015 | 7 | 0.240 |
Why?
|
| Sarcoidosis | 1 | 2006 | 11 | 0.240 |
Why?
|
| Rosacea | 2 | 2016 | 2 | 0.240 |
Why?
|
| Risk Assessment | 13 | 2016 | 863 | 0.240 |
Why?
|
| Prednisolone | 6 | 2012 | 16 | 0.230 |
Why?
|
| Electrocardiography | 2 | 2023 | 185 | 0.230 |
Why?
|
| Lipodystrophy | 1 | 2004 | 7 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 245 | 0.220 |
Why?
|
| Dermatitis, Allergic Contact | 3 | 2012 | 5 | 0.220 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2015 | 5 | 0.220 |
Why?
|
| Speech Disorders | 1 | 2024 | 3 | 0.220 |
Why?
|
| Xanthomatosis | 4 | 2004 | 5 | 0.210 |
Why?
|
| Face | 3 | 2016 | 40 | 0.210 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2003 | 1 | 0.210 |
Why?
|
| Mouth | 1 | 2024 | 54 | 0.210 |
Why?
|
| Respiratory Rate | 1 | 2023 | 11 | 0.200 |
Why?
|
| Monitoring, Physiologic | 1 | 2023 | 39 | 0.200 |
Why?
|
| Aged, 80 and over | 12 | 2016 | 2853 | 0.190 |
Why?
|
| Tensile Strength | 1 | 2022 | 27 | 0.190 |
Why?
|
| Elastic Modulus | 1 | 2022 | 20 | 0.190 |
Why?
|
| Range of Motion, Articular | 1 | 2022 | 37 | 0.190 |
Why?
|
| Microscopy, Atomic Force | 1 | 2022 | 61 | 0.190 |
Why?
|
| Dilatation, Pathologic | 2 | 2012 | 10 | 0.190 |
Why?
|
| Lumbar Vertebrae | 1 | 2022 | 44 | 0.190 |
Why?
|
| Killer Cells, Natural | 4 | 2006 | 104 | 0.190 |
Why?
|
| Korea | 10 | 2009 | 37 | 0.190 |
Why?
|
| Administration, Cutaneous | 2 | 2013 | 48 | 0.180 |
Why?
|
| Cicatrix | 4 | 2013 | 17 | 0.180 |
Why?
|
| Stress, Mechanical | 1 | 2022 | 164 | 0.180 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2012 | 203 | 0.180 |
Why?
|
| Hair | 2 | 2014 | 38 | 0.180 |
Why?
|
| Thigh | 6 | 2015 | 12 | 0.180 |
Why?
|
| Tidal Volume | 1 | 2021 | 9 | 0.170 |
Why?
|
| Diaphragm | 1 | 2021 | 11 | 0.170 |
Why?
|
| Sweat Gland Diseases | 3 | 2008 | 3 | 0.170 |
Why?
|
| Injections, Intralesional | 5 | 2014 | 11 | 0.170 |
Why?
|
| Subcutaneous Tissue | 3 | 2005 | 5 | 0.170 |
Why?
|
| Respiration | 1 | 2021 | 56 | 0.170 |
Why?
|
| Glucocorticoids | 5 | 2010 | 91 | 0.170 |
Why?
|
| Granuloma Annulare | 3 | 2005 | 3 | 0.160 |
Why?
|
| Pseudolymphoma | 3 | 2005 | 5 | 0.160 |
Why?
|
| Herpes Zoster | 3 | 2005 | 12 | 0.160 |
Why?
|
| Epidermal Growth Factor | 2 | 2015 | 70 | 0.160 |
Why?
|
| Nipples | 3 | 2005 | 20 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2005 | 15 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2008 | 291 | 0.150 |
Why?
|
| Infant, Newborn | 3 | 2015 | 972 | 0.140 |
Why?
|
| Recurrence | 3 | 2014 | 152 | 0.140 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 81 | 0.140 |
Why?
|
| Motion | 1 | 2017 | 31 | 0.140 |
Why?
|
| Infant | 10 | 2010 | 1175 | 0.140 |
Why?
|
| Leg Ulcer | 2 | 2016 | 8 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2011 | 38 | 0.130 |
Why?
|
| Skin Diseases, Vascular | 2 | 2008 | 4 | 0.130 |
Why?
|
| Ichthyosis | 3 | 2006 | 4 | 0.130 |
Why?
|
| Atrophy | 2 | 2015 | 51 | 0.130 |
Why?
|
| Mite Infestations | 1 | 2016 | 3 | 0.120 |
Why?
|
| Sweat Gland Neoplasms | 2 | 2006 | 2 | 0.120 |
Why?
|
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2016 | 1 | 0.120 |
Why?
|
| Cosmetic Techniques | 3 | 2014 | 4 | 0.120 |
Why?
|
| Neurilemmoma | 2 | 2009 | 5 | 0.120 |
Why?
|
| Histiocytosis | 2 | 2008 | 2 | 0.120 |
Why?
|
| Nail Diseases | 1 | 2015 | 3 | 0.120 |
Why?
|
| Keratosis | 2 | 2005 | 4 | 0.110 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 118 | 0.110 |
Why?
|
| Facial Neoplasms | 2 | 2007 | 5 | 0.110 |
Why?
|
| Nose Diseases | 1 | 2015 | 2 | 0.110 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2012 | 187 | 0.110 |
Why?
|
| Single-Blind Method | 2 | 2014 | 54 | 0.110 |
Why?
|
| Panax | 1 | 2014 | 6 | 0.110 |
Why?
|
| Ginsenosides | 1 | 2014 | 4 | 0.110 |
Why?
|
| Calcinosis | 2 | 2005 | 62 | 0.110 |
Why?
|
| Skin Diseases, Metabolic | 1 | 2014 | 1 | 0.110 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2014 | 1 | 0.110 |
Why?
|
| Stomach Neoplasms | 2 | 2008 | 241 | 0.110 |
Why?
|
| Keloid | 2 | 2005 | 3 | 0.110 |
Why?
|
| Neck | 5 | 2006 | 20 | 0.110 |
Why?
|
| Cushing Syndrome | 1 | 2014 | 5 | 0.110 |
Why?
|
| Adrenalectomy | 1 | 2014 | 23 | 0.110 |
Why?
|
| Microspheres | 2 | 2012 | 49 | 0.110 |
Why?
|
| Sphingosine | 2 | 2005 | 22 | 0.110 |
Why?
|
| Keratinocytes | 1 | 2014 | 67 | 0.110 |
Why?
|
| Matrix Metalloproteinase 1 | 3 | 2016 | 26 | 0.110 |
Why?
|
| Hemangiopericytoma | 2 | 2005 | 2 | 0.110 |
Why?
|
| Pain | 2 | 2014 | 290 | 0.110 |
Why?
|
| Folliculitis | 2 | 2004 | 2 | 0.110 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2013 | 5 | 0.110 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 3 | 0.100 |
Why?
|
| Prognosis | 5 | 2016 | 861 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2016 | 374 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2006 | 41 | 0.100 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 9 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2013 | 24 | 0.100 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 61 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2014 | 183 | 0.100 |
Why?
|
| Mice | 2 | 2022 | 6644 | 0.100 |
Why?
|
| Administration, Topical | 7 | 2007 | 39 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 186 | 0.100 |
Why?
|
| Viscosupplements | 1 | 2012 | 1 | 0.100 |
Why?
|
| Incidence | 3 | 2013 | 1078 | 0.100 |
Why?
|
| Dapsone | 1 | 2012 | 2 | 0.100 |
Why?
|
| Pressure | 1 | 2012 | 50 | 0.100 |
Why?
|
| Hair Color | 1 | 2012 | 1 | 0.100 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2012 | 12 | 0.100 |
Why?
|
| Minocycline | 1 | 2012 | 6 | 0.100 |
Why?
|
| Fibroblasts | 2 | 2005 | 281 | 0.090 |
Why?
|
| Gene Expression | 1 | 2016 | 701 | 0.090 |
Why?
|
| Vincristine | 2 | 2010 | 14 | 0.090 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2012 | 1 | 0.090 |
Why?
|
| Nutrition Surveys | 1 | 2013 | 263 | 0.090 |
Why?
|
| Cosmetics | 1 | 2012 | 10 | 0.090 |
Why?
|
| Chemexfoliation | 1 | 2012 | 1 | 0.090 |
Why?
|
| Melanosis | 1 | 2012 | 3 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 59 | 0.090 |
Why?
|
| Rare Diseases | 2 | 2010 | 17 | 0.090 |
Why?
|
| Scoliosis | 1 | 2012 | 7 | 0.090 |
Why?
|
| Forehead | 1 | 2011 | 1 | 0.090 |
Why?
|
| Lymphoid Tissue | 1 | 2011 | 19 | 0.090 |
Why?
|
| Sulfonylurea Compounds | 1 | 2011 | 17 | 0.090 |
Why?
|
| Doxorubicin | 2 | 2010 | 97 | 0.090 |
Why?
|
| Animals | 5 | 2022 | 16992 | 0.090 |
Why?
|
| Amphotericin B | 1 | 2011 | 25 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 54 | 0.090 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 224 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2014 | 302 | 0.090 |
Why?
|
| Risk Factors | 4 | 2016 | 3994 | 0.090 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Sebum | 1 | 2011 | 1 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 39 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 113 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 116 | 0.080 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2009 | 89 | 0.080 |
Why?
|
| Sampling Studies | 4 | 2016 | 64 | 0.080 |
Why?
|
| Etoposide | 1 | 2010 | 21 | 0.080 |
Why?
|
| Methylprednisolone | 1 | 2010 | 17 | 0.080 |
Why?
|
| Cyclosporine | 1 | 2010 | 36 | 0.080 |
Why?
|
| Hidradenitis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 55 | 0.080 |
Why?
|
| Mycobacterium chelonae | 1 | 2009 | 2 | 0.080 |
Why?
|
| Liposomes | 1 | 2011 | 132 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2009 | 10 | 0.080 |
Why?
|
| Asthma | 1 | 2013 | 416 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 184 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2016 | 341 | 0.080 |
Why?
|
| Carcinoma, Large Cell | 1 | 2009 | 3 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 242 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2009 | 11 | 0.070 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2009 | 2 | 0.070 |
Why?
|
| Umbilicus | 1 | 2009 | 4 | 0.070 |
Why?
|
| Omentum | 1 | 2009 | 5 | 0.070 |
Why?
|
| Polyarteritis Nodosa | 1 | 2009 | 4 | 0.070 |
Why?
|
| Pseudoxanthoma Elasticum | 1 | 2009 | 32 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2008 | 6 | 0.070 |
Why?
|
| Arthralgia | 2 | 2006 | 12 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2009 | 73 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 53 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2009 | 38 | 0.070 |
Why?
|
| Silver Compounds | 1 | 2008 | 2 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2009 | 71 | 0.070 |
Why?
|
| Argyria | 1 | 2008 | 2 | 0.070 |
Why?
|
| Hypertrophy | 1 | 2008 | 34 | 0.070 |
Why?
|
| Hand Dermatoses | 1 | 2008 | 2 | 0.070 |
Why?
|
| Forearm | 2 | 2005 | 5 | 0.070 |
Why?
|
| Hedgehogs | 1 | 2008 | 4 | 0.070 |
Why?
|
| Osteosarcoma | 1 | 2008 | 30 | 0.070 |
Why?
|
| Bence Jones Protein | 1 | 2008 | 1 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2009 | 127 | 0.070 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2008 | 4 | 0.070 |
Why?
|
| Eyelids | 1 | 2008 | 4 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1455 | 0.070 |
Why?
|
| Zinc | 1 | 2009 | 131 | 0.070 |
Why?
|
| Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
|
| Abdomen | 2 | 2005 | 13 | 0.070 |
Why?
|
| Itraconazole | 2 | 2011 | 13 | 0.070 |
Why?
|
| Survival Rate | 3 | 2016 | 355 | 0.070 |
Why?
|
| Collagen | 2 | 2009 | 181 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2009 | 213 | 0.070 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2007 | 5 | 0.060 |
Why?
|
| Aminoquinolines | 1 | 2007 | 17 | 0.060 |
Why?
|
| Picibanil | 1 | 2006 | 2 | 0.060 |
Why?
|
| Lymphangioma | 1 | 2006 | 5 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2006 | 10 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2005 | 140 | 0.060 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2006 | 5 | 0.060 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sweet Syndrome | 1 | 2006 | 2 | 0.060 |
Why?
|
| Foot | 1 | 2006 | 10 | 0.060 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2006 | 8 | 0.060 |
Why?
|
| Diet | 1 | 2012 | 826 | 0.060 |
Why?
|
| Hidrocystoma | 1 | 2006 | 1 | 0.060 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Leg Dermatoses | 2 | 2004 | 2 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 1 | 2006 | 5 | 0.060 |
Why?
|
| Cholangiocarcinoma | 1 | 2006 | 7 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 117 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2005 | 146 | 0.060 |
Why?
|
| Leg | 2 | 2016 | 19 | 0.060 |
Why?
|
| Piroxicam | 1 | 2005 | 2 | 0.060 |
Why?
|
| Perfume | 1 | 2005 | 2 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2006 | 12 | 0.060 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2006 | 35 | 0.060 |
Why?
|
| Arthrogryposis | 1 | 2005 | 4 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2005 | 2 | 0.060 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2005 | 3 | 0.060 |
Why?
|
| Elastic Tissue | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cholestasis | 1 | 2005 | 12 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 14 | 0.060 |
Why?
|
| Hypertrichosis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 539 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2005 | 23 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 38 | 0.060 |
Why?
|
| Exanthema | 1 | 2005 | 12 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2009 | 561 | 0.060 |
Why?
|
| Angiolipoma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Wrist | 1 | 2005 | 7 | 0.060 |
Why?
|
| Genital Neoplasms, Male | 1 | 2005 | 2 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2005 | 39 | 0.060 |
Why?
|
| Myoepithelioma | 1 | 2005 | 1 | 0.060 |
Why?
|
| Burns | 1 | 2005 | 10 | 0.060 |
Why?
|
| Parotid Neoplasms | 1 | 2005 | 4 | 0.060 |
Why?
|
| Fatigue | 1 | 2006 | 100 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 14 | 0.060 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2005 | 19 | 0.060 |
Why?
|
| Vibrio Infections | 1 | 2005 | 4 | 0.060 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2005 | 3 | 0.060 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2004 | 133 | 0.060 |
Why?
|
| Vibrio vulnificus | 1 | 2005 | 5 | 0.060 |
Why?
|
| Breast Neoplasms | 3 | 2005 | 1723 | 0.060 |
Why?
|
| Calcitriol | 1 | 2005 | 32 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 20 | 0.060 |
Why?
|
| Acanthosis Nigricans | 1 | 2005 | 11 | 0.060 |
Why?
|
| Lung Neoplasms | 3 | 2009 | 495 | 0.060 |
Why?
|
| Neuroma | 1 | 2004 | 1 | 0.050 |
Why?
|
| Bacteremia | 1 | 2005 | 37 | 0.050 |
Why?
|
| Candidiasis | 1 | 2005 | 89 | 0.050 |
Why?
|
| Fat Necrosis | 1 | 2004 | 3 | 0.050 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2004 | 20 | 0.050 |
Why?
|
| Granuloma, Pyogenic | 1 | 2004 | 2 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2004 | 18 | 0.050 |
Why?
|
| Angiolymphoid Hyperplasia with Eosinophilia | 1 | 2004 | 1 | 0.050 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 18 | 0.050 |
Why?
|
| Vasculitis | 1 | 2004 | 4 | 0.050 |
Why?
|
| Mucinosis, Follicular | 1 | 2004 | 1 | 0.050 |
Why?
|
| Silicone Gels | 1 | 2004 | 2 | 0.050 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2004 | 2 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2004 | 10 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2004 | 15 | 0.050 |
Why?
|
| Ketoprofen | 1 | 2003 | 2 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 518 | 0.050 |
Why?
|
| Methotrexate | 1 | 2004 | 22 | 0.050 |
Why?
|
| Sarcoma | 1 | 2004 | 11 | 0.050 |
Why?
|
| 2-Aminopurine | 1 | 2003 | 10 | 0.050 |
Why?
|
| Eosinophilia | 1 | 2004 | 17 | 0.050 |
Why?
|
| Palliative Care | 1 | 2004 | 61 | 0.050 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2003 | 1 | 0.050 |
Why?
|
| Angiokeratoma | 1 | 2003 | 2 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2008 | 367 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2005 | 172 | 0.050 |
Why?
|
| Quinazolines | 1 | 2004 | 38 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2004 | 42 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 37 | 0.050 |
Why?
|
| Psoriasis | 1 | 2003 | 19 | 0.050 |
Why?
|
| Necrobiotic Disorders | 1 | 2003 | 1 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2015 | 368 | 0.050 |
Why?
|
| Collagen Type I | 2 | 2016 | 35 | 0.050 |
Why?
|
| Skin Abnormalities | 1 | 2003 | 1 | 0.050 |
Why?
|
| Hemangioma, Capillary | 1 | 2003 | 2 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 61 | 0.050 |
Why?
|
| Dermatomyositis | 1 | 2003 | 9 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 290 | 0.050 |
Why?
|
| Malassezia | 1 | 2003 | 6 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2003 | 49 | 0.050 |
Why?
|
| Scabies | 1 | 2002 | 1 | 0.050 |
Why?
|
| Urticaria Pigmentosa | 1 | 2002 | 1 | 0.050 |
Why?
|
| Antigens | 1 | 2003 | 59 | 0.050 |
Why?
|
| Biocompatible Materials | 1 | 2004 | 108 | 0.050 |
Why?
|
| Tinea Capitis | 1 | 2002 | 1 | 0.050 |
Why?
|
| Diagnostic Errors | 1 | 2002 | 21 | 0.050 |
Why?
|
| Diaper Rash | 1 | 2002 | 1 | 0.050 |
Why?
|
| Myxedema | 1 | 2002 | 1 | 0.050 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sebaceous Gland Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2002 | 29 | 0.050 |
Why?
|
| Epidermal Cyst | 1 | 2002 | 1 | 0.050 |
Why?
|
| Granular Cell Tumor | 1 | 2002 | 1 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2003 | 124 | 0.050 |
Why?
|
| Erythema Nodosum | 1 | 2002 | 2 | 0.050 |
Why?
|
| Tattooing | 1 | 2002 | 7 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2002 | 24 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2003 | 140 | 0.040 |
Why?
|
| Syndrome | 3 | 2006 | 73 | 0.040 |
Why?
|
| Lasers | 1 | 2002 | 57 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 458 | 0.040 |
Why?
|
| Pancreatic Neoplasms | 1 | 2004 | 218 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2002 | 75 | 0.040 |
Why?
|
| Carcinoma | 1 | 2002 | 108 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2021 | 12 | 0.040 |
Why?
|
| Acoustics | 1 | 2021 | 17 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 1857 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 101 | 0.040 |
Why?
|
| Lymph Nodes | 2 | 2016 | 74 | 0.040 |
Why?
|
| Fatal Outcome | 3 | 2009 | 48 | 0.040 |
Why?
|
| Leiomyoma | 1 | 2002 | 42 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2016 | 1271 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2002 | 383 | 0.040 |
Why?
|
| Patch Tests | 2 | 2012 | 4 | 0.040 |
Why?
|
| Apoptosis | 2 | 2004 | 1568 | 0.040 |
Why?
|
| Caustics | 2 | 2012 | 2 | 0.040 |
Why?
|
| Trichloroacetic Acid | 2 | 2012 | 2 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2013 | 224 | 0.040 |
Why?
|
| Age Distribution | 2 | 2013 | 249 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 667 | 0.030 |
Why?
|
| Steroids | 2 | 2010 | 45 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2009 | 36 | 0.030 |
Why?
|
| Mites | 1 | 2016 | 9 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 1028 | 0.030 |
Why?
|
| Collagen Type II | 1 | 2016 | 3 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2016 | 6 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 7 | 0.030 |
Why?
|
| Natural Killer T-Cells | 1 | 2016 | 11 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Erythema Multiforme | 1 | 2015 | 1 | 0.030 |
Why?
|
| Parakeratosis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Lichenoid Eruptions | 1 | 2015 | 1 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Arm | 2 | 2006 | 28 | 0.030 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2016 | 28 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 29 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2016 | 45 | 0.030 |
Why?
|
| Toes | 2 | 2006 | 6 | 0.030 |
Why?
|
| Fever | 2 | 2006 | 62 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 95 | 0.030 |
Why?
|
| Lentigo | 1 | 2015 | 1 | 0.030 |
Why?
|
| Water Loss, Insensible | 1 | 2015 | 1 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.030 |
Why?
|
| Iduronate Sulfatase | 1 | 2014 | 1 | 0.030 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Dihydrotestosterone | 1 | 2014 | 28 | 0.030 |
Why?
|
| Injections | 1 | 2014 | 42 | 0.030 |
Why?
|
| Keratins | 2 | 2005 | 26 | 0.030 |
Why?
|
| Buttocks | 2 | 2005 | 3 | 0.030 |
Why?
|
| Triamcinolone | 2 | 2004 | 3 | 0.030 |
Why?
|
| Base Sequence | 2 | 2008 | 983 | 0.030 |
Why?
|
| Vimentin | 2 | 2005 | 44 | 0.030 |
Why?
|
| Ceramides | 2 | 2005 | 44 | 0.030 |
Why?
|
| Necrosis | 2 | 2005 | 54 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 2013 | 23 | 0.030 |
Why?
|
| S100 Proteins | 2 | 2005 | 13 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 144 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2013 | 53 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2005 | 260 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2008 | 1542 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 518 | 0.020 |
Why?
|
| Hydroa Vacciniforme | 1 | 2012 | 1 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 196 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Chlorphenesin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Benzalkonium Compounds | 1 | 2012 | 2 | 0.020 |
Why?
|
| Immunophenotyping | 2 | 2002 | 57 | 0.020 |
Why?
|
| Thiazoles | 1 | 2012 | 76 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 986 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1154 | 0.020 |
Why?
|
| Bowen's Disease | 1 | 2011 | 4 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 165 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1759 | 0.020 |
Why?
|
| Elastin | 1 | 2010 | 40 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2005 | 1621 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 196 | 0.020 |
Why?
|
| Clarithromycin | 1 | 2009 | 9 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 224 | 0.020 |
Why?
|
| Genes, Recessive | 1 | 2009 | 8 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2009 | 10 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1869 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2009 | 20 | 0.020 |
Why?
|
| Triamcinolone Acetonide | 1 | 2008 | 3 | 0.020 |
Why?
|
| Colloids | 1 | 2008 | 15 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2008 | 11 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2009 | 139 | 0.020 |
Why?
|
| Program Development | 1 | 2009 | 240 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2008 | 58 | 0.020 |
Why?
|
| Gels | 1 | 2008 | 45 | 0.020 |
Why?
|
| Filtration | 1 | 2007 | 17 | 0.020 |
Why?
|
| Sclerotherapy | 1 | 2006 | 3 | 0.020 |
Why?
|
| Anal Canal | 1 | 2006 | 32 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2006 | 6 | 0.020 |
Why?
|
| Lipoma | 1 | 2006 | 5 | 0.020 |
Why?
|
| Atropine | 1 | 2006 | 12 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2006 | 69 | 0.020 |
Why?
|
| Mastectomy, Radical | 1 | 2005 | 1 | 0.020 |
Why?
|
| Norisoprenoids | 1 | 2005 | 2 | 0.020 |
Why?
|
| Pentanols | 1 | 2005 | 3 | 0.020 |
Why?
|
| Ankle Injuries | 1 | 2005 | 3 | 0.020 |
Why?
|
| Propanols | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cyclohexenes | 1 | 2005 | 3 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 24 | 0.010 |
Why?
|
| Telangiectasis | 1 | 2005 | 1 | 0.010 |
Why?
|
| Plant Oils | 1 | 2005 | 20 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 432 | 0.010 |
Why?
|
| Cyclopentanes | 1 | 2005 | 26 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 2005 | 37 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2006 | 113 | 0.010 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 15 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2005 | 24 | 0.010 |
Why?
|
| Sesquiterpenes | 1 | 2005 | 38 | 0.010 |
Why?
|
| Neutropenia | 1 | 2005 | 11 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 94 | 0.010 |
Why?
|
| Aldehydes | 1 | 2005 | 70 | 0.010 |
Why?
|
| Cryotherapy | 1 | 2005 | 11 | 0.010 |
Why?
|
| Scrotum | 1 | 2005 | 4 | 0.010 |
Why?
|
| Allergens | 1 | 2005 | 65 | 0.010 |
Why?
|
| Shoulder | 1 | 2005 | 10 | 0.010 |
Why?
|
| Penile Neoplasms | 1 | 2005 | 12 | 0.010 |
Why?
|
| Mast Cells | 1 | 2005 | 82 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 49 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 114 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2005 | 17 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 167 | 0.010 |
Why?
|
| Pancreatic Function Tests | 1 | 2004 | 1 | 0.010 |
Why?
|
| Ossification, Heterotopic | 1 | 2004 | 1 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 88 | 0.010 |
Why?
|
| Hand | 1 | 2004 | 34 | 0.010 |
Why?
|
| Paronychia | 1 | 2004 | 1 | 0.010 |
Why?
|
| Acneiform Eruptions | 1 | 2004 | 1 | 0.010 |
Why?
|
| Spectral Karyotyping | 1 | 2004 | 2 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 164 | 0.010 |
Why?
|
| Urticaria | 1 | 2004 | 5 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2009 | 735 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 19 | 0.010 |
Why?
|
| Injections, Intramuscular | 1 | 2003 | 21 | 0.010 |
Why?
|
| Prednisone | 1 | 2003 | 31 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2004 | 70 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 153 | 0.010 |
Why?
|
| Cervical Vertebrae | 1 | 2003 | 18 | 0.010 |
Why?
|
| Isotretinoin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Keratolytic Agents | 1 | 2003 | 3 | 0.010 |
Why?
|
| Lower Extremity | 1 | 2004 | 38 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2003 | 15 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 92 | 0.010 |
Why?
|
| Mucinoses | 1 | 2003 | 1 | 0.010 |
Why?
|
| Connective Tissue | 1 | 2003 | 7 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 211 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 173 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 22 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 234 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 138 | 0.010 |
Why?
|
| Ketoconazole | 1 | 2003 | 8 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 311 | 0.010 |
Why?
|
| World Health Organization | 1 | 2003 | 36 | 0.010 |
Why?
|
| Toluidines | 1 | 2002 | 3 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2003 | 127 | 0.010 |
Why?
|
| Europe | 1 | 2003 | 115 | 0.010 |
Why?
|
| Sodium Benzoate | 1 | 2002 | 1 | 0.010 |
Why?
|
| Diet, Protein-Restricted | 1 | 2002 | 6 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2002 | 6 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 174 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 9 | 0.010 |
Why?
|
| Sebaceous Glands | 1 | 2002 | 3 | 0.010 |
Why?
|
| Citrulline | 1 | 2002 | 14 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2002 | 17 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 455 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2002 | 23 | 0.010 |
Why?
|
| Neutrophils | 1 | 2003 | 145 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 2002 | 6 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 138 | 0.010 |
Why?
|
| Remission, Spontaneous | 1 | 2002 | 2 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2002 | 39 | 0.010 |
Why?
|
| Ankle | 1 | 2002 | 4 | 0.010 |
Why?
|
| Coma | 1 | 2002 | 7 | 0.010 |
Why?
|
| Glasgow Coma Scale | 1 | 2002 | 21 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 611 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 587 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 75 | 0.010 |
Why?
|
| Mastectomy | 1 | 2002 | 21 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 2003 | 93 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 195 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 1285 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 945 | 0.010 |
Why?
|
| Genotype | 1 | 2002 | 800 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 1772 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2004 | 2157 | 0.010 |
Why?
|